Study summary · research use only
[Thymalin as a modulator of immunogenesis and hemostasis]
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
This human study (species not specified beyond human patients) examined thymalin in 30 patients with periodontosis. The abstract reports that thymalin was associated with improvement in patients' general health status, promoting normalization of cellular immunity and, to a lesser degree, humoral immunity. The drug was also reported to normalize blood coagulation, total fibrinolysis, and Hageman factor-dependent fibrinolysis. The authors describe thymalin as a modulator of immunogenesis and hemostasis based on these findings.
Abstract
Studies made in 30 patients with periodontosis have shown that thymaline improves the general health status of patients, thereby promoting the normalization of cellular and, to a lesser degree, humoral immunity. At the same time the drug normalizes blood coagulation, the total and Hageman factor-dependent fibrinolysis. It is concluded that thymaline is a modulator of the immunogenesis and hemostasis.
pepmg summarizes the peer-reviewed literature and links to every source. It sells nothing and ships nothing. Where an FDA label, a peer-reviewed study or a clinical-trial registry entry (labeled trial registry, not peer-reviewed) has published a dose, pepmg reports it with the source named; it gives no personalized recommendations and no administration technique. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.